As cancer services continue to make headlines in the fall out of the pandemic, Proactive Investors talks to Oncimmune Holdings PLC (LONONC) CEO Adam Hill about today's full trading update.
Hill talks us through the first full trading year for the company's ImmunoINSIGHTS platform which enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients.
The company believes the key to improving cancer survival is early detection and better selection for therapy, to give patients that precious extra time.
There's news here too on Oncimmune's EarlyCDT Lung rollout which targets a vast market estimated to grow to £3.8bn by 2024.